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Background. Postthrombotic syndrome (PTS) is a burdensome and costly complication of deep vein thrombosis (DVT). Up to
50% of patients with DVT will develop the disease within two years following the diagnosis of acute DVT. Various risk factors for
developing PTS have been identified and diﬀerent modalities have been used to prevent its development. Compression stockings
have been studied for the prevention of PTS in patients diagnosed with proximal DVT.Methods. MEDLINE and EMBASE databases
were searched to identify relevant original articles. Results. Several trials including two metaanalyses have examined the role of
compression stockings for the prevention of PTS. Although most trials showed significant reduction in the development of PTS
with the use of compression stockings, limitations in study design prevent the generalizability of the data. Two studies supported
an individualized tailored duration especially in patients at low risk for developing the syndrome. A randomized double-blind
placebo-controlled trial involving 800 patients is currently ongoing and may confirm the results of older studies. Conclusions.
Clinical trials support the use of compression stockings in patients diagnosed with proximal DVT for the prevention of PTS.
1. Introduction
Postthrombotic syndrome (PTS) is a severe and common
chronic complication of deep vein thrombosis (DVT) of
the lower extremity. Between 20% and 50% of patients
diagnosed with and adequately treated for a DVT will
be aﬀected with PTS within the following two- to five-
years; with most cases being reported within the first two
years [1–7]. However, the exact incidence and prevalence
of PTS remain elusive due to inconsistency in the diagnosis
of PTS, underreporting of most DVTs, and the lack of
standardization of the definition of PTS [8]. In a population-
based study published in 2000, the cumulative rates of PTS
following the diagnosis of DVT ranged from 7% at 1 year
to 27% at 20 years [9]. However, as the number of patients
diagnosed with DVT is increasing in the United States and
reaching 250,000 new cases annually, the prevalence and thus
incidence of PTS will likely follow suit [10].
Classical features of PTS range from mild to severe and
are diﬃcult to quantify. The Villalta score combines signs
and symptoms in a graded system and is recognized as
the best tool in defining PTS [8]. Signs and symptoms of
PTS include aching pain while standing, burst of pain while
walking, edema, and itching of the aﬀected limb [11, 12].
In severe PTS, aﬀecting 10% of patients, intractable limb
ulceration is common and is often a result of trauma [12].
The constellation of these symptoms leads to restricted
mobility, limited daily activities, and adversely aﬀects quality
of life [13–17]. In fact, it is estimated that 2 million workdays
are lost in the United States every year due to leg ulcers
[18].
Healthcare costs for treating PTS vary among studies
[16–22]. Some report that the mean incremental adjusted
healthcare cost of developing PTS was approximately $7000/
patient/year whereas others report a much lower rate of
$400–$1200/patient/year [21, 22]. Nonetheless, there is
agreement that the costs are significant and so, treatment
is often ineﬀective that perhaps a better strategy may be to
focus on the prevention of PTS. Therefore, the purpose of
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this article is to describe the available literature on the use of
compression stockings in preventing PTS in adult patients.
2. Pathophysiology
The pathophysiology of PTS is not well defined. It is
postulated that PTS occurs as a result of chronic venous
hypertension that develops due to valvular reflex and residual
thrombus. When a patient develops a DVT, damage to
venous valves ensues as a result of acute thrombus, the
process of vein recanalization, release of inflammatory me-
diators, fibrous scaring, or venous dilation with increased
tissue permeability. These factors alone or in combination
lead to valvular incompetence or reflux [23–26]. Moreover,
treatment of a DVT with various anticoagulants prevents
the extension and embolization of the thrombus rather than
enhancing its clearance through disintegration. This leads
to persistent venous obstruction due to residual thrombus.
Of the two mechanisms leading to venous hypertension, the
presence of residual thrombus alone or in combination with
valvular reflux predicts the development of PTS more than
valvular reflux alone. Thus, persistent venous obstruction
due to the presence of residual thrombus appears to be a
more important factor in the development of PTS [27–31].
3. Diagnostic Tools
The diagnosis of PTS is based on clinical findings in patients
with previously confirmed diagnosis of DVT of the aﬀected
limb. These findings represent a collection of nonspecific
signs and symptoms with a high degree of interpatient vari-
ability resulting in the classification of PTS as a syndrome.
In some patients, the pain and swelling associated with the
initial DVT making take up to 6 months to resolve and
thus the diagnosis of PTS should be deferred to after the
acute phase of DVT has elapsed to allow time for after
revascularization symptoms of the initial DVT to resolve
[1, 32].
Patients with PTS usually experience limb heaviness
or fatigue, chronic pain, itching, cramping, and numbness
that are worse with standing or activity and relieved with
rest and elevation. Symptoms are typically present with
varying frequency and intensity and are patient-specific.
Physical examination of the limb may reveal edema, telan-
giactasias, hyperpigmentation, venous eczema, secondary
varicose veins, and lipodermatosclerosis. In severe cases, leg
ulcers requiring medical attention may be observed [1, 33]
(Table 1).
Invasive and noninvasive diagnostic tools can be used
to confirm the diagnosis of PTS especially in patients who
present with symptoms of the syndrome but do not have
a confirmed diagnosis of DVT. These tools should not,
however, be utilized in the absence of clinical features for
PTS as many patients with DVT will have abnormal findings
similar to those presenting with PTS. Thus, the diagnosis
of PTS is based on clinical presentation irrespective of
the abnormalities shown by these diagnostic tools [43–45].
Contrast venography is an invasive, expensive tool used to
Table 1: Clinical Features of PTS.
Symptoms; worse with activity Signs
Pain Edema
Swelling Hyperpigmentation
Heaviness Venous eczema
Fatigue Telangiactasias
Tingling Secondary varicose veins
Itching Lipodermatosclerosis
Cramps Redness, cyanosis
Bursting sensation Ulcers
identify findings that suggest a previous DVT. Compression
ultrasonography along with continuous-wave Doppler scan
are noninvasive measures that evaluate the compressibility of
common femoral and popliteal veins and the reflux of venous
valves. These diagnostic tests are especially helpful in patients
who have features of PTS but without a history of DVT.
Computed tomography venography and magnetic resonance
venography can delineate thrombotic obstruction to plan
for interventions. Three clinical scales utilize combinations
of clinical signs and imaging to assess the presence and/or
severity of PTS. These scales all recognize some combination
of subjective signs and symptoms in patients with DVT
after revascularization and vary in their consideration and
weighting of objective evidence via plethysmography and/or
venous Doppler and their incorporation of rating scales
of significance of signs and symptoms. The Villalta scale
combines patient limb symptoms and signs in a graded
scoring system; the higher the score, the greater the severity
of PTS. The Clinical-Etiology-Anatomic-Pathophysiologic
(CEAP) scale has parameters that include clinical findings
and subcategories to designate etiology, anatomic distri-
bution, and pathophysiology [34–37, 40, 46] (Table 2). In
an attempt to standardize the definition and measurement
of PTS, the Subcommittee on Control of Anticoagulation
of the Scientific and Standardization Committee of the
International Society on Thrombosis and Haemostasis rec-
ommended the Villalta scale be adopted to diagnose and
grade PTS in clinical research [8].
4. Risk Factors for PTS
A variety of clinical and patient-specific risk factors have
been implicated in the development of PTS. These will
be categorized into those that are evident at the time of
diagnosis or during initial treatment of DVT, and those that
develop in the long-term period following the management
of DVT.
5. Risk Factors Evident at the Time or during
Initial Treatment of DVT
5.1. Clinical Features. A definitive correlation between PTS
and the type of DVT, whether it is idiopathic or provoked
(cancer-related or modifiable risk factors), has not been
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Table 2: Clinical Scales for assessing the presence and severity of PTS.
PTS Scale Criteria used to diagnose PTS Comments
Ginsberg et al. [34]
Pain and swelling of limb > 1 month duration, typical character (worse at
end of day or with prolonged sitting/standing, better after night’s rest and
leg elevation) that occurs ≥ 6 months after acute DVT
AND
Objective evidence of valvular incompetence (diagnosed via
plethysmography or venous Doppler):
(i) if both criteria are present, PTS is diagnosed,
(ii) Global Rating Questionnaire used to rate overall improvement or
worsening of PTS over time
Developed specifically for
PTS; does not rate the
severity of PTS
Villalta et al. [35]
5 Symptoms (pain, cramps, heaviness, pruritus, paresthesia)
6 signs (edema, skin induration, hyperpigmentation, ectasia, redness, pain
during calf compression)
Each rated as 0 (absent), 1 (mild), 2 (moderate) or 3 (Severe)
Points are summed. A total score of
0–4: No PTS
5–14: Mild/Moderate PTS
≥15, or presence of ulcer: Severe PTS
Developed specifically for
PTS; rates the severity of
PTS
CEAP Classification∗ [36, 37]
Patients with chronic venous disease classified into 1 of 7 clinical classes
(Class 0–6) according to the presence of clinical signs. Each class may
include signs present in lower-order class.
Class†:
(0) Symptoms only; no visible or palpable signs of venous disease
(1) Telangiectasias, reticular veins, malleolar flare
(2) Varicose veins
(3) Edema, no skin changes
(4) Skin changes (e.g., pigmentation, eczema, lipodermatosclerosis)
(5) Skin changes with healed ulcer
(6) Skin changes with active ulcer
Each clinical class is then subclassified as to:
Etiology (congenital, primary, secondary)
Anatomy (superficial, deep, perforator veins)
Pathophysiology (reflux, obstruction, both)
Was developed for chronic
venous disease in general
and not for PTS; does not
rate the severity of PTS
PTS = postthrombotic syndrome; ∗CEAP: Clinical-Etiology-Anatomic-Pathophysiologic. Modifications of CEAP (clinical severity score, venous segmental
disease score) have been proposed.
†Increasing CEAP class is intended to reflect increased severity of signs of chronic venous disease; symptoms and their severity are not considered.
established in prospective studies [7, 47, 48]. Moreover, data
from various studies regarding the association between the
development of PTS and location of the initial DVT have
been inconclusive due to diﬀerences in study design, patient
selection, and PTS definition. For instance, in some studies,
patients presenting with proximal DVT were reported to
have a higher incidence of developing PTS compared to those
presenting with distal (calf) DVT [48–51]. In a prospec-
tive cohort study, patients with more extensive proximal
DVT and increased clinical findings at 1 month were at
an increased risk for developing PTS 2 years following
DVT diagnosis. This could be attributed to persistence
of residual thrombus [5]. However, literature from other
studies reported up to 80% incidence of PTS in patients
presenting with distal (calf) DVT; thus suggesting that this
type of DVT may be associated with a considerable risk of
PTS development [52, 53]. Moreover, pulmonary embolism
without concomitant ultrasonographically detectable DVT
does not predispose patients to PTS [54].
Finally, patients who develop DVT but are asymptomatic
have an overall relative risk of 1.6 (95% CI 1.24–2.02)
compared to patients without DVT [55]. In a prospective
study, 20% of asymptomatic patients diagnosed with DVT
following screening after total knee and total hip arthroplasty
developed PTS by the 18-month followup period [56]. In a
retrospective review of 1037 patients who underwent total
hip arthroplasty, 21 patients developed DVT on postopera-
tive day 3 when screened as part of the study protocol; 14 of
which had a minimum of 1-year followup. Three of the 14
patients developed PTS compared to two out of 91 randomly
matched patients without DVT [57].
5.2. Patient-Specific. It is unclear whether an association
exists between increasing age, gender, and the development
of PTS. Although two studies found a relationship between
age and PTS, others did not [7, 13, 47, 48, 58]. Similarly,
female gender has been inconsistently associated with PTS,
while male gender was reported to be a weak risk [48,
59]. A correlation was confirmed, however, between PTS
and obesity [60]. In a small cohort study of patients with
DVT, those who developed PTS had significantly higher
BMI than those who did not (29.6 versus 27.2 kg/m2,
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resp.; P = 0.022) [61]. This finding was confirmed by
other studies and thusmerits further evaluation ofmodifying
obesity for PTS prevention and management [47, 58].
Although thrombophilic disorders predispose patients to
developing first and recurrent DVT, the association to PTS
has not been confirmed [62, 63]. Factor V Leiden or the
prothrombin 20210A mutation were not associated with the
development of PTS; in fact, one study showed a decreased
risk when these factors were present [7, 48, 58, 60, 64].
Finally, inflammatory markers such as interleukin-6
and C-reactive protein are elevated in patients with DVT;
however, an association between these markers and the
development of PTS was not fully elucidated in a prospective
study [62, 63, 65].
6. Risk Factors That Develop in the Long-Term
Period Following the Management of DVT
6.1. Clinical Features. There is conclusive evidence that a
recurrent ipsilateral DVT increases the risk of developing
PTS by up to ten folds when compared with controls [2, 5, 7].
Further damage of valves and obstruction of blood flow
due to recurrent DVT may be attributed to the increased
incidence of PTS. In a study involving 316 patients with
DVT, the risk for recurrent DVT was higher in patients
with residual thrombus and led to increased vascular death
resulting in vascular dysfunction [66]. Thus, preventing DVT
in moderate-to-high-risk patients and providing adequate
therapy for treatment are crucial to prevent recurrent DVT
and consequently PTS.
Although residual thrombosis plays an important role
in recurrent DVT, the association to PTS is not definitive.
Two studies examined this issue; one found no association,
while another reported an odds ratio of 1.69 (95% CI 1.23–
2.32) [29]. Moreover, the role of residual thrombosis and
popliteal valve reflux in the development of PTS was assessed
in 180 patients diagnosed with acute proximal DVT followed
for a minimum of 3 years. The relative risk was 1.6 (95%
CI 1.0–2.4) in patients with residual vein thrombosis and
1.7 (95% CI 1.2–2.3) in patients with persistent venous
obstruction alone or combined with popliteal valve reflux
[29, 67]. In another study involving 93 patients with distal
and proximal DVT followed up to 6 years, valve reflux had
a predictive value while residual thrombosis had a weak-
to-no association [29, 58]. These results were confirmed
in another study which reported an association between
elevated peak reflux velocity and the development of PTS
[68].
Finally, a weak association between elevated D-Dimer
levels after the withdrawal of anticoagulants and the devel-
opment of PTS was reported (OR 1.9, 95% CI 1.0–3.9).
Since D-Dimer has been implicated in predicting thrombotic
recurrences, its role in the PTS should be further investigated
[69, 70].
6.2. Patient-Specific. The quality of anticoagulation therapy
when given to manage acute thrombosis constitutes a risk
factor for the development of PTS. A study of patients treated
with Vitamin K antagonists for a mean of 3 months (target
INR 2.0-3.0) revealed an association in patients who had a
subtherapeutic INR for more than 50% of the time and the
development of PTS. In these patients, the risk was increased
by about 3 folds and could be attributed to suboptimal
clot resolution due to the poor quality of anticoagulation
[47]. The intensity of anticoagulation was also examined
in another study involving patients treated for unprovoked
proximal DVT for an average of 2.2 years. Patients were
randomized to a target INR of 2.0-3.0 or 1.5–1.9. The study
did not find a diﬀerence in developing PTS between the two
groups [58]. Finally, in a cohort study of 406 patients treated
for a first DVT for a median of 60 months, there was no
association between the duration of therapy (<6 months, 6–
12 months, or >12 months) and the development of PTS
[48].
7. Prevention of PTS
There are various measures to prevent PTS in patients
diagnosed with acute DVT. These include preventing recur-
rent ipsilateral DVT, modifying risk factors such as obesity,
treating venous obstruction via stenting and angioplasty, and
surgically repairing or replacing venous valves [7, 20, 47, 58,
71, 72]. Moreover, catheter, directed thrombolysis has also
shown to improve valvular reflux and vein patency and is rec-
ommended for selected patients diagnosed with iliofemoral
DVT by practice guidelines [73–75].
Graduated elastic compression stockings can also be
used in the management of PTS due to their eﬀects on
decreasing edema and venous hypertension, and improving
tissue microcirculation [76]. The current guideline for the
management of venous thromboembolism disease provides
the highest recommendation for elastic compression stock-
ings (Grade 1A) in those patients diagnosed with a DVT so,
there is minimal patient risk and cost with high likelihood
of preventing PTS [75]. This recommendation is based
upon the results from several trials that support the use of
compression stockings in the prevention of PTS. Brandjes et
al. randomized 194 patients diagnosed with a first episode of
proximal DVT to either daily use of sized-to-fit graded elastic
compression stockings (40mmHg at the ankle, 36mmHg
at the lower calf, and 21mmHg at the upper calf) for at
least two years or no stockings (control group). Proximal
DVT included thrombi involving the popliteal vein or
above, irrespective of the presence of calf vein thrombi.
All patients received treatment with heparin for at least
5 days and continued on Coumadin for 3 months. Mild-
to-moderate PTS occurred in 20% of patients receiving
stockings compared to 47% in the control group (P < 0.001),
whereas severe PTS occurred in 11% of patients receiving
stockings compared to 23% in the control group (P <
0.001). In both groups, most cases of PTS occurred within 24
months of the acute DVT event. There was no diﬀerence in
recurrence of DVT between the two groups [38]. Similarly, in
a study by Prandoni and colleagues, 180 patients with a first
episode of proximal DVT were randomly assigned to below-
knee compression stockings (30–40mmHg) for two years
or no stockings (control group). The cumulative incidence
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Table 3: Study Characteristics.
First author/year
published
Reference
Number of patients
per group
(Stocking/Control)
Stocking characteristics Stocking duration Followup
Brandjes et al. 1997 [38] 96/98
Graduate compression stocking
below knee
(i) 40mmHg at ankle
(ii) 36mmHg at lower calf
(iii) 21mmHg at upper calf
≥2 years ≥5 years in both
groups
Partsch and Bla¨ttler 2000 [39] 30/15
Inelastic compression bandages
[Unna boots on the lower leg,
adhesive bandages on the thigh]
(n = 15) or Thigh-length
compression stockings (n = 15)
9 days None
Ginsberg et al. 2001 [40] 42/40
Elastic compression stocking below
knee (n = 38) or thigh (n = 4)
(i) 20–30mmHg
1.4–4.6 years
1.4–4.6 years in
stocking group;
1.8–4.9 years in
control group
Partsch et al. 2004 [41] 26/11
Thigh length elastic compression
stocking (n = 13) or Gauze zinc
oxide and calamine impregnated
bandage on lower leg and firm thigh
adhesive bandage (n = 13)
2 years
2 years in both
groups
Prandoni et al. 2004 [7] 90/90
Graduate below-knee compression
elastic stockings
(i) 30 to 40mmHg at the ankle
2 years
3–5 years in
both groups
Aschwanden et al. 2008 [42] 84/85
Compression stocking below knee
(i) 26.3–36.1mmHg at ankle
3.2 years
3.2 years in the
stocking group;
2.9 years in
control group
of PTS in patients with stockings versus the control group
was reduced after 6 months (21.1% versus 40%, resp.), 1-
year (22.2% versus 46.7%, resp.), and 2 years (24.5% versus
49.1%, resp.) [7].
In contrast, in a 3-part study by Ginsberg and coau-
thors, 47 patients diagnosed with first episode of proximal
DVT (involving the popliteal or more proximal vein) with
evidence of venous valvular incompetence were randomized
to either below-knee stockings (20–30mmHg) or matched
placebo stockings. There was no statistical diﬀerence in the
development of PTS between patients allocated to stockings
versus placebo (0% versus 4.3%, resp.; P = 0.49) within
a mean followup period of 57 months. However, the small
number of patients enrolled in this study precludes definitive
conclusions [40]. A study of acute proximal DVT, 53
patients were randomized to bed rest and no compression,
boot bandages plus walking, or compression stockings plus
walking, the authors reported a reduction in the incidence
and severity of PTS in the mobile group with compression
compared to the bed rest group (assessed by the Villalta-
Prandoni scale; P < 0.01) [41]. These findings were
consistent with another similarly designed trial conducted
by the same primary author [39]. A more recent study
by Ashwanden et al. randomized 169 patients with a first
or recurrent proximal DVT to either ready-to wear flat-
knitted below-knee stockings (26.3 to 36.1mmHg) or no
stockings (control group). Proximal DVT included thrombi
involving the popliteal vein or more proximal veins (femoral
and iliac). All patients received heparin initially followed
by an oral anticoagulation and compression stockings for
at least 6 months. After finishing the 6 months of therapy,
patients were randomized to continue treatment with either
stockings or no stockings. The primary end point defined
as the occurrence of emerging Postthrombotic skin changes
according to a CEAP classification of 4 or greater developed
in 13.1% of patients in the stocking group compared to
20.0% in the control group (hazard ratio [HR], 0.60; 95%
CI, 0.28–1.28; P = 0.19) with a mean followup of 3.2 years
and 2.9 years, respectively. Five additional patients in the
control group requiring compression therapy for PTS were
not included in the primary end point. Of note, women
in the stocking group experienced a significant reduction
in the development of severe skin changes (HR, 0.11; 95%
CI, 0.02–0.91) compared to men (HR, 1.07; 95% CI, 0.42–
2.73). This gender diﬀerence could be attributed to increased
compliance as men were found to be 4 times less likely to
wear the stockings compared to women (odds ration [OR],
4.1; CI, 1.0–16.0; P = 0.05) [42]. (Table 3) Individualized
duration of elastic compression therapy to prevent PTS was
also assessed in a study involving 125 patients with acute
proximal DVT involving the popliteal, femoral, or common
femoral veins. Results were consistent with findings from
the trial by Ten Cate-Hoek et al. suggesting that patients
with a low probability of developing the syndrome can be
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identified as early as 6 months after the thrombotic event
[77].
Furthermore, a metaanalysis of the first three trials
including a total of 421 patients supported the use of com-
pression stockings (30–40mmHg) after DVT in reducing the
risk of any PTS (odds ratio [OR] 0.3; 95% CI; 0.2–0.48) and
of severe PTS (OR 0.39; 95% CI; 0.2–0.76) [78]. In a recent
metaanalysis of 5 randomized trials including a total of 580
patients with DVT, mild-to-moderate PTS occurred in 22%
of patients treated with compression stockings compared to
37% in the control group (relative risk = 0.52). Severe PTS
and any PTS occurred in 5% and 26% of patients treated with
compression stockings compared to 12% and 46% in the
control group, respectively (relative risk = 0.38 and relative
risk = 0.54, resp.) [79].
Although these data support using compression stock-
ings to reduce the development of PTS, each previously
mentioned trial had limitations that could aﬀect the general-
izability of the results. These include small sample size, single
center recruitment, and bias due to lack of blinding and
subjectivity of some elements of the scales used to diagnose
PTS. The SOX Trial is a double-blind multicenter study that
is currently under investigation to evaluate the eﬀectiveness
of compression stockings in the prevention of PTS. A total of
800 patients with proximal DVT will be randomly assigned
to either compression stockings worn on the aﬀected leg
for 2 years or inactive stockings (placebo). The results of
this trial should help answer questions regarding the use of
compression stockings given the limitations of the previous
trials [80].
8. Conclusion
PTS is a burdensome and costly syndrome that may aﬀect up
to 50% of patients diagnosed with DVT within the first two
years. Studies have identified risk factors for developing this
syndrome including obesity, older age, and poor quality of
anticoagulation therapy. Several modalities have been used
to prevent the development of PTS including compression
stockings. The role of compression stockings including use
and duration of use will be further clarified and confirmed
with ongoing research. Limitations to using the compression
stockings include compliance which is necessary to optimize
eﬀectiveness. It has been suggested that knee-length stock-
ings are easier to apply and more comfortable than thigh-
length stockings with similar physiologic outcomes [81].
Moreover, individualizing duration of treatment may also
increase compliance.
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